The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 87,014 |
| Depreciation expense | 1,509 |
| Gain on disposal of fixed asset | 13 |
| Stock-based compensation expense | 28,696 |
| Non-cash lease expense | 2,410 |
| Accounts receivable | 825 |
| Prepaid expenses and other current assets | -4,018 |
| Current income tax receivable | 2,250 |
| Other assets | -2,056 |
| Accounts payable | -3,001 |
| Right-of-use assets and operating lease liabilities | 1,978 |
| Accrued expenses and other current liabilities | -10,131 |
| Net cash provided by (used in) operating activities | 107,505 |
| Purchase of property and equipment | 1,551 |
| Net cash used in investing activities | -1,551 |
| Proceeds from issuance of common stock-Secondary Offering | 0 |
| Payment of issuance costs | 0 |
| Proceeds from issuance of common stock-At The Market Offering | 0 |
| Payment of issuance costs associated with issuance of common stock under the atm agreement | 0 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 138 |
| Repurchase of treasury stock | 375,000 |
| Payment of direct expenses associated with the treasury stock repurchase | 3,897 |
| Short-swing profit settlement | 139 |
| Proceeds from exercise of stock options | 150 |
| Net cash provided by (used in) financing activities | -378,470 |
| Net change in cash, cash equivalents and restricted cash | -272,516 |
| Cash, cash equivalents and restricted cash at beginning of year | 561,380 |
| Cash, cash equivalents and restricted cash at end of year | 288,864 |
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)